Welcome to our dedicated page for Cadrenal Therape SEC filings (Ticker: CVKD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) SEC filings page on Stock Titan provides centralized access to the company’s U.S. regulatory disclosures, including Current Reports on Form 8-K, proxy materials, and other documents filed with the Securities and Exchange Commission. As an emerging growth biopharmaceutical company focused on anticoagulant therapies, Cadrenal uses these filings to report material events, governance matters, and financing activities that shape its clinical and corporate trajectory.
Investors researching CVKD can use this page to review Form 8-K filings that describe offerings of common stock and warrants, at-the-market equity programs, and other capital-raising transactions. Additional 8-K reports furnish quarterly financial results, including research and development spending and general and administrative expenses, which help illustrate how resources are being allocated to programs such as tecarfarin, frunexian, and VLX-1005.
The company’s definitive proxy statement on Schedule 14A offers detail on board composition, annual meeting proposals, and governance practices. Over time, annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) provide broader context on risk factors, clinical development plans, and the status of regulatory designations for Cadrenal’s anticoagulation pipeline.
Stock Titan enhances this document set with AI-powered summaries that explain the key points of lengthy filings in plain language. Users can quickly understand the implications of a new financing, changes in capital structure, or updates to clinical strategy without reading every page. The platform also surfaces insider and beneficial ownership information when disclosed, helping users see how management and major holders are aligned with the company’s progress. With real-time updates from EDGAR and AI-generated insights, this page is designed to make Cadrenal’s regulatory record more accessible and easier to interpret.
Cadrenal Therapeutics, Inc. is updating its at-the-market equity program to offer and sell up to $3,438,062 of common stock through H.C. Wainwright & Co. as sales agent or principal. Based on an assumed price of $11.61 per share, this corresponds to up to 296,129 shares, which would raise Cadrenal’s common stock outstanding from 2,075,845 to as many as 2,371,974 shares if fully sold. Wainwright will receive a 3.0% sales commission on gross proceeds. The company plans to use any net proceeds for working capital and general corporate purposes, including potential acquisitions, licensing or investments in product candidates or other intellectual property, and possible repurchases of securities. The filing highlights that the ATM structure may lead to price variation and potential dilution for new and existing shareholders.
Cadrenal Therapeutics (CVKD) submitted an 8-K announcing it furnished a press release with financial information for the quarter ended September 30, 2025, under Item 2.02.
The company states this information, including Exhibit 99.1, is furnished and not deemed filed, and is not incorporated by reference into other SEC filings. The press release was issued on November 10, 2025.
Cadrenal Therapeutics (CVKD) reported a larger year-to-date loss and flagged liquidity risk. Net loss was $2.69 million for Q3 2025 and $10.20 million for the nine months ended September 30, 2025. Operating expenses for the nine months rose to $10.40 million, driven by higher G&A of $6.96 million (up 73%) and R&D of $3.43 million (up 29%). Interest and dividend income contributed $0.20 million year to date.
Cash and cash equivalents were $3.86 million as of September 30, 2025, after $10.03 million used in operating activities year to date. Management states these factors raise substantial doubt about the company’s ability to continue as a going concern. To bolster liquidity, Cadrenal raised $3.83 million net via its ATM during the nine months and a further approximately $0.22 million net after quarter-end.
On September 12, 2025, Cadrenal acquired eXIthera assets, including frunexian (EP-7041) and EP-7327. The company paid $50,000 at closing and expensed $151,216 in transaction costs, with contingent milestones of up to $15 million, a 2% royalty on future net sales, and 50% of royalties received under the Haisco license.
Cadrenal Therapeutics (CVKD) reported insider transactions by its Chief Financial Officer, Matthew K. Szot. He sold 1,800 shares of common stock on October 24, 2025, and 1,800 shares on October 27, 2025, each at $13.99 per share, coded as open‑market sales (S).
The filing states these trades were executed under a Rule 10b5-1 trading plan adopted on May 9, 2025. Following the reported sales, the officer directly beneficially owns 9,933 shares.
Cadrenal Therapeutics (CVKD): CEO/Chairman Quang Pham reported open‑market sales under a Rule 10b5‑1 plan. On 10/24/2025, he sold 1,129 shares of common stock at a weighted average price of $14.03, with trades ranging from $13.99 to $14.10. On 10/27/2025, he sold 1,315 shares at a weighted average price of $13.99, with trades ranging from $13.99 to $14.00. The trading arrangement was adopted on May 9, 2025.
Following these transactions, direct beneficial ownership was 197,404 shares after the first sale and 196,089 shares after the second. He also holds 200,000 shares indirectly through The PVBQ Living Trust, for which he serves as trustee with sole voting and disposition power.
Cadrenal Therapeutics (CVKD) reported an insider transaction by its Chief Financial Officer. On 10/09/2025, the CFO sold 1,693 shares of common stock at $13.99, and on 10/13/2025, sold 1,800 shares at $14.07, in each case under a Rule 10b5-1 trading arrangement. Following these sales, the CFO directly beneficially owned 13,533 shares.
Cadrenal Therapeutics (CVKD) reported insider transactions by CEO, Chairman and Director Quang Pham, who is also a 10% owner. Under a Rule 10b5-1 trading arrangement, he sold 1,800 shares on 10/09/2025 at a weighted average price of $14.02 and 1,800 shares on 10/13/2025 at a weighted average price of $14.15. Each sale comprised multiple trades within disclosed price ranges.
Following these transactions, Mr. Pham directly beneficially owns 198,533 shares. He also indirectly beneficially owns 200,000 shares through The PVBQ Living Trust, for which he is trustee with sole voting and disposition power.
Cadrenal Therapeutics, Inc. (CVKD) filed a Form 144 reporting a proposed public sale of 1,693 common shares valued at $23,634.28 to be sold through Morgan Stanley Smith Barney LLC on 10/09/2025 on NASDAQ. The shares were originally issued as founders' shares on 05/17/2022 and were acquired from the issuer.
The filing also lists multiple recent 10b5-1 plan sales by the same seller totaling several thousand shares over 08/27/2025–10/06/2025, including a single sale of 10,900 shares on 09/25/2025 for $153,182.06. The filer attests there is no undisclosed material information and identifies the broker and planned sale date.
Cadrenal Therapeutics, Inc. (CVKD) notice shows an insider intends to sell 1,800 common shares, with an aggregate market value of $25,227.76, on 10/09/2025 via Merrill Lynch on NASDAQ. The shares were acquired as founders shares on 01/25/2022. The filing also discloses several recent secondary sales by the same person, totaling 15,200 shares sold across dates from 08/27/2025 to 10/02/2025 with cumulative gross proceeds of $242,044.83. The filer attests they have no undisclosed material adverse information and the form includes a standard attestation about Rule 10b5-1 plan timing if applicable.
Cadrenal Therapeutics (CVKD) Chief Financial Officer Matthew K. Szot reported a sale of common stock under a prearranged trading plan. The Form 4 shows a disposition of 107 shares at $13.99 per share on 10/06/2025, leaving the reporting person with 17,026 shares beneficially owned. The filing indicates the sale was made pursuant to a Rule 10b5-1 arrangement and is signed by the reporting person.